Lorin Carroll
Payments from drug & device makers
Across 182 payments — averaging $20.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$547
- Lilly USA, LLC$455
- AbbVie$439
- AstraZeneca$410
- Otsuka America Pharmaceutical, Inc.$274
- GSK$177
- plus $1K from 18 others
What the payments were for
- Food & beverage$3,717100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 26 | $547 |
| Lilly USA, LLC | 23 | $455 |
| AbbVie | 19 | $439 |
| AstraZeneca | 21 | $410 |
| Otsuka America Pharmaceutical, Inc. | 16 | $274 |
| GSK | 8 | $177 |
| Amgen | 10 | $175 |
| Pfizer | 8 | $151 |
| Dexcom, Inc. | 7 | $138 |
| Exact Sciences | 6 | $136 |
| Bayer | 5 | $131 |
| Boehringer Ingelheim | 5 | $109 |
| Lundbeck LLC | 5 | $104 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $101 |
| Antares Pharma, Inc. | 5 | $94 |
| Astellas Pharma US Inc | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Edwards Lifesciences | 1 | $43 |
| Idorsia Pharmaceuticals US Inc | 2 | $38 |
| Exeltis, USA Inc. | 1 | $24 |
| Optinose US, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Merck | 1 | $20 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
How this compares
$3,717 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 32 | $45,260 |
| JardianceEmpagliflozin | 34 | $39,633 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $37,624 |
| RexultiBrexpiprazole | 22 | $36,460 |
| RybelsusSemaglutide | 22 | $27,599 |
| OzempicSemaglutide | 19 | $21,193 |
| FarxigaDapagliflozin Propanediol | 15 | $18,291 |
| Repatha SyringeEvolocumab | 18 | $15,045 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $12,048 |
| KerendiaFinerenone | 15 | $11,003 |
| EliquisApixaban | 14 | $10,657 |
| Emgality PenGalcanezumab-Gnlm | 14 | $9,949 |
| SynthroidLevothyroxine Sodium | 15 | $1,540 |
| Rosuvastatin Calcium | 112 | $944 |
| Ibuprofen | 42 | $779 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $547 | $48,79341 claims |
| Lilly USA, LLCMounjaro | $455 | $45,26032 claims |
| Boehringer IngelheimJardiance | $109 | $39,63334 claims |
| GSKTrelegy Ellipta | $177 | $37,62443 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $274 | $36,46022 claims |
| AstraZenecaFarxiga | $410 | $18,29115 claims |
| BayerKerendia | $131 | $11,00315 claims |
| PfizerEliquis | $151 | $10,65714 claims |
| AbbVieSynthroid | $439 | $1,54015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.
Other family in Tampa
- Lewis HarringtonTampa$954K
- Natasha WickTampa$126K
- Marie Labadie-DegennaroTampa$66K
- Polly BittleTampa$63K
- Katharine WilliamsTampa$47K
- Candace DeberryTampa$46K
- Bailey BlankenshipTampa$42K
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.